Treatment of ocular disease
View Patent ↗Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
1. A method of reducing ocular edema in a human in need thereof comprising administering to the human a therapeutically-effective amount of a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) binding agent, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody or the antigen-binding fragment thereof binds to a FN3 domain in the HPTPβ-ECD.
2. The method of claim 1 , wherein the HPTPβ-ECD binding agent is administered in a composition, wherein the composition comprises a pharmaceutically-acceptable carrier.
3. The method of claim 1 , wherein the ocular edema is retinal edema.
4. The method of claim 1 , wherein the ocular edema is diabetic macular edema.
5. The method of claim 1 , wherein the therapeutically-effective amount is from about 0.01 mg/kg to about 10 mg/kg by weight of the human.
6. The method of claim 1 , wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated to a vehicle.
7. The method of claim 6 , wherein the vehicle is polyethylene glycol.
8. The method of claim 1 , wherein the HPTPβ-ECD binding agent is administered by intraocular injection.
9. The method of claim 1 , wherein the HPTPβ-ECD binding agent is administered by subcutaneous injection.
10. The method of claim 1 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection.
11. A method of reducing diabetic macular edema comprising administering to a human in need thereof a composition comprising a therapeutically-effective amount of a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) binding agent, wherein the HPTPβ-ECD binding agent is a monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody or the antigen-binding fragment thereof binds to a FN3 domain in the HPTPβ-ECD.
12. The method of claim 11 , wherein the composition comprises a pharmaceutically acceptable carrier.
13. The method of claim 11 , wherein the therapeutically-effective amount is from about 0.01 mg/kg to about 10 mg/kg by weight of the human.
14. The method of claim 11 , wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated to a vehicle.
15. The method of claim 14 , wherein the vehicle is polyethylene glycol.
16. The method of claim 11 , wherein the HPTPβ-ECD binding agent is administered by intraocular injection.
17. The method of claim 11 , wherein the HPTPβ-ECD binding agent is administered by subcutaneous injection.
18. The method of claim 11 , wherein the HPTPβ-ECD binding agent is administered by intravenous injection.